Steven Berman, MD
Infectious Disease · Honolulu, HINPI 1245207182
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $368 of the $484 with a category attached, or 76.0%. 7 manufacturers reported payments, led by AstraZeneca at 40.9% of the total. Reporting peaked in 2024 at $260 and has fallen 88.4% since, to $30 in 2025. That places this record below the midpoint for infectious disease clinicians in HI, where the typical reported total is $484.
Across 22 payments — averaging $22.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$198
- Novo Nordisk$148
- Viiv Healthcare Company$61
- Melinta Therapeutics, LLC$27
- Merck$26
- AbbVie$18
- plus $6 from 1 others
What the payments were for
- Food & beverage$36876%
- Education$11624%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 10 | $198 |
| Novo Nordisk | 3 | $148 |
| Viiv Healthcare Company | 3 | $61 |
| Melinta Therapeutics, LLC | 2 | $27 |
| Merck | 2 | $26 |
| AbbVie | 1 | $18 |
| Forte Bio-pharma LLC | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$116
How this compares
$484 in reported general payments places this provider in the 50th percentile of 28 infectious disease providers in Hawaii.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Efavirenz-Emtric-Tenofov DisopEfavirenz/Emtricit/Tenofovr Df | 25 | $27,805 |
| JanumetSitagliptin Phos/Metformin Hcl | 17 | $24,260 |
| JanuviaSitagliptin Phosphate | 14 | $21,449 |
| JardianceEmpagliflozin | 16 | $20,638 |
| EliquisApixaban | 15 | $16,905 |
| FarxigaDapagliflozin Propanediol | 11 | $15,604 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 15 | $12,473 |
| Atorvastatin Calcium | 158 | $5,820 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 67 | $2,309 |
| Celecoxib | 27 | $1,693 |
| Ezetimibe | 21 | $1,422 |
| Novolin NInsulin Nph Human Isophane | 11 | $1,266 |
| Omeprazole | 38 | $1,220 |
| Losartan Potassium | 50 | $753 |
| Tamsulosin Hcl | 33 | $734 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanumet, Januvia, Janumet Xr | $26 | $58,18246 claims |
| AstraZenecaFarxiga | $198 | $15,60411 claims |
| AbbVieSynthroid | $18 | $3111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 28 infectious disease providers in Hawaii.
Other infectious disease in Honolulu
- Brian PienHonolulu$19K
- Takashi ShinhaHonolulu$12K
- Francis PienHonolulu$10K
- Heath ChungHonolulu$6K
- Russell WongHonolulu$5K
- Benjamin ThomasHonolulu$3K
- Lorrance MajewskiHonolulu$2K
- James JoynerHonolulu$2K
- Erlaine BelloHonolulu$828
- Rashmi BaragiHonolulu$247
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.